New findings in antiaggregation treatment for ESC 2010

Authors: J. Špác
Published in: Kardiol Rev Int Med 2011, 13(1): 59-61
Category: Congress Reports


Attention at last year’s European Cardio­logical Congress in the field of antiaggregation treatment was chiefly focused on improving the effectiveness of treatment and reduction of risk for patients. A number of papers focused on the influencing of treatment through the incidence of genetic polymorphisms during clopidogrel treatment, drug interactions between proton pump inhibitors and clopidogrel. The clinical results of the second-phase study in the field of new drug groups were presented for thrombin inhibitors, as they were for non-thienopyridine antiaggregational substances, e.g. elinogrel. The question of how best to monitor antiaggregation treatment – either through the monitoring of pharmacological effects or the monitoring of an individual’s genetic make-up – remained unresolved for the time being.

antiaggregation treatment – acute coronary syndromes


1. Trenk D, Hochholzer W, Fromm MF et al. ­Cytochrome P450 2C19 681G>A Polymorphism and High ­On-Clopidogrel Platelet Reactivity Associated With ­Adverse 1-Year Clinical Outcome of Elective Percuta­neous ­Coronary Intervention With Drug-Eluting or ­Bare-Metal Stents. J Am Coll Cardiol 2008; 51: 1925–1934.

2. Wallentin L, James S, Storey RF et al. PLATO investigators. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010; 376: 1320–1328.

3. Paré G, Mehta SR, Yusuf S et al. Effects of CYP2C19 genotype on clopidogrel treatment in CURE and ACTIVE. N Eng J Med 2010; 363: 1704–1714.

4. Bhatt DL, Cryer BL, Contant CF et al. COGENT ­Investigators. Clopidogrel with or without Omeprazole in Coronary Artery Disease. N Engl J Med 2010; 363: 1909–1917.

5. Simon T, Verstuyft C, Mary-Krause M et al. French Registry of Acute ST-Elevation and ­Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardio­vascular events. N Engl J Med 2009; 360: 363–375.

6. Abraham NS, Hlatky MA, Antman EM et al. American College of Cardiology Foundation Task Force on Expert Consensus Documents. ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thieno­pyridines: A ­Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastro­intestinal Risks of Antiplatelet Therapy and NSAID Use. J Am Coll Cardiol 2010; 56: 2051–2066.

7. Geisler T et al. Impact of inflammatory markers on platelet function and cardiovascular outcome in patiens under­going coronary intervention. ESC 2010.

8. Rao S. The INNOVATE PCI investigators. A randomized, double-blind, active controlled trial to evaluate intravenous and oral PRT060128 (elinogrel), a selective and reversible P2Y12 receptor inhibitor vs clopidogrel as a novel antiplatelet therapy in patients undergoing nonurgent percutaneous coronary interventions. European Society of Cardiology 2010 Congress; 2010; August 30, 2010; Stockholm, Sweden.

Paediatric cardiology Internal medicine Cardiac surgery Cardiology
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account